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ABSTRACT The endogenous opioid system includes three major families of peptides: dynorphins 
(derived from pre-proenkephalin B), endorphins (derived from pre-proopiomelanocortin), and enke-
phalins (derived from pre-proenkephalin A). Multiple species of opioid peptides are derived from these 
major precursors and many of them possess potent cardiovascular properties. Opioid peptides and 
opioid receptors, of which multiple forms have been defined, are present in the central nervous system 
and peripheral neural elements. In the central nervous system, opioid peptides and receptors are found 
in forebrain and hindbrain nuclei involved in baroregulation, sympathoadrenal activation, and several 
other vital autonomic functions. In the periphery, opioid peptides are found in autonomic ganglia, 
adrenal gland, heart, and other organs; multiple opioid receptors are also found in vascular tissue, 
heart, and kidneys. Although little is known to date on the regulatory mechanisms of the opioid system 
in normal cardiovascular states, it became clear that cardiovascular stress situations substantially 
modify the activity of the endogenous opioid system. The purpose of this review is to clarify the sites of 
interaction of the opioid system with all major components of the cardiovascular system and indicate 
the potential role of this system in the ontogenesis of cardiac malfunction, vascular diseases, and 
hypertension. 
Circulation 75(suppl I), 1-125, 1987. 
OPIATES are among the oldest pharmacologic sub-
stances known to man. Besides analgesia, one of the 
earlier (1824) observations on the biological activity of 
morphine and other opiate alkaloids was the demon-
stration of potent cardiorespiratory effects of these 
agents. 1-4 The cardiac, respiratory, and blood pressure 
effects of morphine were reported by several authors in 
the second half of the 19th century. 3, 5, 6 Since the dis-
covery of opioid peptides and the identification of mul-
tiple opioid receptors in the heart and brain nuclei 
involved in cardiorespiratory control,?' 8 the role of 
opioid peptides in autonomic regulation of blood pres-
sure, heart function, and respiration became even more 
complex. Endogenous opioid peptides are a heteroge-
neous group of pep tides , which in spite of some impor-
tant structural similarities differ from each other in 
respect to synthesis, distribution, release, and actions. 9 
Their actions are mediated by a family of receptors that 
may recognize different opiates and opioid peptides in 
different ways to yield variable, sometimes opposing, 
cardiovascular effects. The presence or absence of an-
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esthetics can drastically change opiate effects. The aim 
of this review is to focus on the conflicting experimen-
tal data on the cardiovascular actions of opioid pep-
tides and to summarize the present knowledge on the 
role of the opioid system in cardiovascular control and 
their possible significance in the pathophysiology of 
hypertension. 
Site and mode of the cardiovascular actions of opiates and 
opioid peptides. Opioid peptides and their receptors are 
present in brain areas important for cardiovascular 
control, in heart, in autonomic ganglia, and in adrenal 
medulla. 7, 9-12 Exogenous opioid peptides/opiates in-
duce different effects on blood pressure and heart rate 
depending on the route of administration or on anesthe-
sia. Pressor responses and tachycardia follow the later-
al brain ventricular administration,13 but hypotension 
and bradycardia are observed after systemic injections 
of morphine or opioid peptides. 13, 14 The differences in 
effects of opioids after systemic vs central administra-
tion are of~en used to indicate lack of penetration in 
sufficient quantities to the cardiovascular sites in the 
brain. However, the controversy between these routes 
of administration can be the result of opposite effects 
of the peptide in different brain sites, resulting in sum-
mation response with little or no effect on the gross 
cardiovascular variables. For example, Feuerstein and 
Faden 15 found pressor and depressor sites for morphine 
and D-Ala2 ,D-Leu5-enkephalin (DADL) in neighbor-
ing hypothalamic nuclei, which were less than 1 mm 
apart from each other. Opposite blood pressure re-
sponses can be recorded also after injections of various 
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enkephalin analogs into the anterior hypothalamic area 
of pentobarbitone-anesthetized rats vs conscious ani-
mals: hypotension accompanied by bradycardia in the 
anesthetized vs increases in blood pressure and heart 
rate in the conscious rat. I 6-18 Since the discovery of 
multiple opiate receptors in the brain,12, 19,20 new data 
on the specific effects mediated by different receptors 
have accumulated. Development of new selective 
agonists and antagonists for the appropriate opioid re-
ceptors has made it possible to study the effects of 
different opioid receptor stimulation in different brain 
nuclei. For example, D-Ala2-MePhe4-GlyS-ol-enke-
phalin (DAGO) and morphiceptin are highly selective 
ligands for the mu-receptor,21, 22 DADL a relative spe-
cific agonist for delta-receptor,23 and dynorphin A and 
the benzomorphan derivatives such as bremazocine are 
considered to act mainly on the kappa opioid recep-
tor. 24, 25 By means of stereotactic microinjections into 
the discrete brain nuclei associated with cardiovascular 
control, it has been shown that DAGO is about 100-
fold more potent than DADL in inducing hypotension 
and bradycardia upon injections into the anterior hypo-
thalamus of pentobarbitone-anesthetized rats. 16 Simi-
larily, DAGO microinjected into the nucleus tractus 
solitarius is over lO-fold more potent than DADL in 
eliciting increases in blood pressure and heart rate in 
the spontaneously breathing or artifically respirated 
rat. 26 Qualitative differences in the cardiovascular 
effects of various opiate agonists can also be observed 
when kappa-receptor agonists are compared with 
mu/delta agonists. 27 
The interference of the opioid peptides with the 
autonomic nervous pathways suggests involvement of 
both the sympathetic and parasympathetic nervous 
systems in the cardiovascular actions of these peptides. 
An activation of the sympathoadrenomedullary axis 
seems to underly the pressor and tachycardiac re-
sponses to the mu-agonist DAGO or the delta-agonist 
DADL in the conscious rat. 18, 28, 29 The bradycardic 
effects of various enkephalin analogs, on the other 
hand, have been attributed to an activation of the va-
gus, 18,30,31 although the potent respiratory depressant 
effect may be the main determinant of this effect. 16-18,27 
The plasma vasopressin levels have been shown to be 
depressed after intracerebroventricular32, 33 and intra-
hypothalamic injections28 of opioid peptides, but no 
correlation between the effect of opioids on vasopres-
sin on the one hand and blood pressure on the other 
hand have been demonstrated. In conclusion, the car-
diovascular effects of opioid peptides seem to be medi-
ated mainly by activation of the sympathetic nervous 
system, although a vagal component is likely to be 
1-126 
involved in some of their effects, whereas the release 
of vasopressin seems not to be important to the cardio-
vascular actions of opioid peptides. 
The opioid system in hypertension. Hypertension is as-
sociated with significant changes in the opioid system. 
For example, the levels of dynorphins and leu-enke-
phalin in the pituitary gland and several brain nuclei 
are substantially different in spontaneously hyperten-
sive rats (SHR) as compared with the normotensive 
animals. 34 Alterations in the brain opioid receptors in 
both experimental and genetic hypertension have also 
been reported,35-37 The opioid system has been impli-
cated in the development of high blood pressure in 
SHR, since the pressor responses to intracerebroven-
tricularly administered opioid peptides in SHR are en-
hanced compared with those in normotensive 
rats. 32 , 33, 38, 39 The partial opioid antagonist diprenor-
phine was also shown to produce a more pronounced 
hypotensive response in SHR than in normotensive 
Wistar-Kyoto rats (WKY),39 whereas naloxone failed 
to affect blood pressure in either renal or genetic hy-
pertensive rats. 35 Recently, it was shown in our labora-
tory that SHR differ also from normotensive rats in 
their response to hypothalamic adminsitration of enke-
phalins; the SHR showed an augmented pressor re-
sponse to the mu-agonist DAGO or the delta-agonist 
DADL microinjected into the medial preoptic nucleus 
of hypothalamus. These enkephalin analogs had little 
effect on heart rate of SHR, whereas in normotensive 
WKY a pronounced tachycardia accompanied the 
pressor response. 28 Again, the selective mu-agonist 
was more potent in the pressor effect than the delta-
agonist. 
The antihypertensive drug clonidine was reported to 
increase ,B-endorphin release from the brain slices of 
SHR,40 whereas opiate antagonists blunt the hypoten-
sive effect of clonidine. 41 ,42 However, contradicting 
findings have recently been reported by Conway et 
a1. 43 and Head and de Jong,44 who found no evidence 
for involvement of endogenous opioid peptides in the 
effects of clonidine on blood pressure or plasma cate-
cholamines. Since clonidine (an antihypertensive 
agent) lowers blood pressure, and exogenous opioid 
peptides can induce both hypertensive and hypotensive 
effects, these findings might further indicate a role of 
the endogenous opioid system in the development and/ 
or maintenance of essential hypertension. 
Cardiac effects of opiates. The heart is known to con-
tain both opioid peptides and opioid receptors. The 
enkephalins found in the heart are located in nerve 
endings. 45 The enkephalins46 were shown to decrease 
the chronotropic response of isolated spontaneously 
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beating rat atria to adrenergic agonists. The reduction 
in catecholamine-induced tachycardia was related to 
inhibition of Ca++ accumulation by the rat atria. 47 In 
the spontaneously beating guinea pig atria, however, 
leu-enkephalin augmented the chronotropic response 
to norepinephrine. 48 The inotropic response to norepi-
nephrine in this preparation was not affected by either 
naloxone (a potent opiate antagonist) or by leu-enke-
phalin. Interestingly, the augmentation by leu-enke-
phalin of the chronotropic response to norepinephrine 
was also accompanied by a naloxone reversible incre-
ment in Ca++ uptake by atrial preparation. 48 Although 
the above cited data provide conflicting results on the 
nature of enkephalin modulation of cardiac rhythm by 
catecholamines (which might well represent species 
differences), they clearly show that opioid peptides, 
through activation of opioid receptors, have a primary 
action on the heart. 
These pharmacologic studies are supported by bio-
chemical data showing the presence of opiate receptors 
in the heart. Such evidence has been raised for the first 
time by Simantov et al. ,49 who detected specific bind-
ing of dihydromorphine and naloxone to membranes 
from whole hearts of rats and guinea pigs. However, in 
these original studies only very low levels of specific 
binding could be shown (5%). These studies were fur-
ther supported by the results of Burnie,50 who used a rat 
right ventricular preparation and diprenorphine as a 
nonselective opiate ligand. In none of these studies 
was the type of the opioid receptor in the heart 
characterized. 
More recently, we have shown that most of the 
specific binding of diprenorphine to cardiac muscle 
membranes is found in the atria, in which receptor 
density is almost twice that in the right ventricle and 
threefold over the binding found in the left ventricle. 7 
Characterization of these binding sites by sequential 
displacement of diprenorphine by selective ligands to 
the delta-receptor (DADL), the mu-receptor (DAGO), 
or the kappa-receptor (ethylketocyclazocine) strongly 
suggested the presence of delta- and kappa- but not the 
mu-receptor in the right atrium or ventricle. Interest-
ingly, the binding of diprenorphine to membrane prep-
arations from the right atrium revealed unusual cooper-
ative binding.7 
Furthermore, the opioid receptors found in the right 
ventricle and the right atrium can be down-regulated 
(by - 45% and - 60%, respectively) after acute bleed-
ing (hemorrhage); the number of opiate receptors in the 
heart remains low as much as 24 hr after the bleeding. 
This phenomenon is opposite to the effect of hemor-
rhage on opiate receptor number in the brain, when up-
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regulation of delta- and kappa-binding sites are appar-
ent in the brain stem of rats exposed to hypo volemic 
hypotension. 51 The difference between the central and 
peripheral opiate receptor response to hemorrhage 
might be the result of excessive enkephalins/endor-
phins in the circulation after bleeding52 and down-regu-
lation phenomenon as a result of excessive agonist. 
The significance of the presence of kappa-receptors 
in the heart is less clear, since circulating levels of 
dynorphin A (the putative endogenous kappa-receptor 
ligand) has not been determined as yet. However, in-
travenous administration of the kappa-agonist ethylke-
tocyclazocine to dogs53 or rats54 can slow the heart rate. 
These data taken together further support a role for 
selective opioid peptides and receptors in regulation of 
cardiac functions. 
Vascular tissue and the opioid system. The role of the 
opioid system in regulation of vascular smooth muscle 
tone is poorly investigated. Yet, various opioid pep-
tides are found in the circulation and elevated levels of 
opioid peptides in the plasma are found during cardio-
vascular stress situations (e.g., hypovolemia). The 
opioid peptides in the circulation might be derived 
from the pituitary gland ,B-endorphin), the adrenal 
gland (enkephalins), or even peripheral organs such as 
the heart (dynorphin). 
In vitro, opiate compounds like morphine, cyclazo-
cine, and others have been shown to contract rat aortic 
strips. 55 The contractions produced in aortic strips by 
the opiates were highly dependent on Ca++ and were 
blocked by naloxone and verapamil (calcium entry 
blocker). These studies were substantiated later by oth-
ers, showing that natural and synthetic opiates can 
contract rat aortic strips; however, the latter studies 
also showed that other blood vessels from the same 
species respond with profound relaxation (mesenteric 
arterioles), whereas muscular venules do not respond 
to the narcotic agents. 56 These authors have also shown 
that naloxone or HI (histamine) receptors can prevent 
the narcotic induced vasodilation of the rat mesenteric 
arterioles, indicating an indirect mechanism (hista-
mine dependent) for the narcotic effect on some blood 
vessels. Nevertheless, these pharmacologic studies 
strongly suggest the presence of opiate receptors in the 
vascular smooth muscle. Further studies on the cellular 
mechanisms of opiate interaction with vascular smooth 
muscle indicate that morphine-induced relaxation of 
the cat middle cerebral artery is the result of hyperpo-
larization of the muscle cells, which enhances relax-
ation. 57 This phenomenon was blocked by naloxone, 
indicating that opiate receptors are involved in the 
electromechanical effects of morphine on the smooth 
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muscle cell. These latter studies have also suggested a 
role of opiates in regulation of K + conductance in 
vascular smooth muscle. 
Yet some effects of the opioids on smooth muscle 
tone might be mediated through naloxone-insensitive 
receptors. Thus, pulmonary vasoconstriction pro-
voked by leu5-enkephalin in isolated rat lungs is not 
blocked by naloxone. 58 This finding was further sub-
stantiated by the demonstration of the lack of an effect 
of other opiates and opioid peptides (e.g., morphine or 
met5-enkephalin) in this same smooth muscle prepara-
tion. Moreover, the lack of effect of diprenorphine or 
DADL on this preparation was argued to exclude delta-
opiate receptors as mediator of the leu5-enkephalin ef-
fect on the rat pulmonary artery. 59 However, in a dif-
ferent species, the rabbit, opiate-induced inhibition of 
norepinephrine release from the ear artery was argued 
to be predominantly mediated through delta-opiate 
receptors. 60 
The nature of the opioid effects on vascular smooth 
muscle is further complicated by the demonstrations 
that the opioid peptide dynorphin A(I-13), a preferen-
tial endogeneous ligand for the kappa-opiate receptors, 
inhibits vascular smooth muscle contractions produced 
by electrical stimulation; in this regard, dynorphin 
A(I-13) is more potent than mu- or delta-opioid agon-
ists. 61 
In summary, it is apparent that opiates and opioid 
peptides have direct effects on vascular smooth muscle 
tone. However, it is also clear that some opiate effects 
on vascular smooth muscle might not be direct (e.g., 
histamine mediated) or may not involve a naloxone-
sensitive opiate receptor. It is also clear that the nature 
of the opioid effects on vascular tone varies according 
to the species and even in the same species, between 
different vascular beds. Mu-, delta-, and the kappa-
opiate receptors seem to have some role in the different 
species and vascular preparations tested so far. The 
potential role of the opioids/opioid receptors in vascu-
lar tone regulation in hypertension remains to be 
elucidated. 
We thank Mary Mills for her help in preparing this manu-
script. 
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